Leptin-Replacement Therapy for Lipodystrophy
Elif A Oral, Vinaya Simha, Elaine Ruiz et al. · New England Journal of Medicine · 2002
BACKGROUND: The adipocyte hormone leptin is important in regulating energy homeostasis. Since severe lipodystrophy is associated with leptin deficiency, insulin resistance, hypertriglyceridemia, and hepatic steatosis, we assessed whether leptin replacement would ameliorate this condition. METHODS: Nine female patients (age range, 15 to 42 years; eight with diabetes mellitus) who had lipodystrophy and serum leptin levels of less than 4 ng per milliliter (0.32 nmol per milliliter) received recombinant methionyl human leptin (recombinant leptin). Recombinant leptin was administered subcutaneously twice a day for four months at escalating doses to achieve low, intermediate, and high physiologic replacement levels of leptin. RESULTS: During treatment with recombinant leptin, the serum leptin level increased from a mean (+/- SE) of 1.3 +/- 0.3 ng per milliliter to 11.1 +/- 2.5 ng per milliliter (0.1 +/- 0.02 to 0.9 +/- 0.2 nmol per milliliter). The absolute decrease in the glycosylated hemoglobin value was 1.9 percent (95 percent confidence interval, 1.1 to 2.7 percent; P=0.001) in the eight patients with diabetes. Four months of therapy decreased average triglyceride levels by 60 percent (95 percent confidence interval, 43 to 77 percent; P<0.001) and liver volume by an average of 28 percent (95 percent confidence interval, 20 to 36 percent; P=0.002) in all nine patients and led to the discontinuation of or a large reduction in antidiabetes therapy. Self-reported daily caloric intake and the measured resting metabolic rate also decreased significantly with therapy. Overall, recombinant leptin therapy was well tolerated. CONCLUSIONS: Leptin-replacement therapy improved glycemic control and decreased triglyceride levels in patients with lipodystrophy and leptin deficiency. Leptin deficiency contributes to the insulin resistance and other metabolic abnormalities associated with severe lipodystrophy.
Cited by 1,235 works. doi:10.1056/nejmoa012437 Open-access PDF
Authors
- Elif A Oral
- Vinaya Simha
- Elaine Ruiz
- Alexa Andewelt
- Ahalya Premkumar
- Peter G Snell
- Anthony J. Wagner
- Alex M. DePaoli
- Marc L. Reitman
- Simeon I. Taylor
- Phillip Görden
- Abhimanyu Garg
References
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
- Positional cloning of the mouse obese gene and its human homologue
- Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
- Effects of the obese Gene Product on Body Weight Regulation in ob / ob Mice
- Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks
- Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
- The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
- Role of leptin in the neuroendocrine response to fasting
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
- Congenital leptin deficiency is associated with severe early-onset obesity in humans